Globus Medical Inc.
Management s Discussion and Analysis of Financial Condition and Results of Operations, and Item 7A. Quantitative and Qualitative Disclosure About Market Risk and those discussed in other documents we file with the Securities and Exchange Commission (the SEC ).
$76.71
-$2.13 (-2.70%)
EOD Oct 16, 2026
16.33% operating margin is respectable but not wide. ROIC at 8.77%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 16.7% YoY with margins expanding 9.7pp.
Even for strong businesses, today's 20x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
19.7x earnings, 13.6x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3.14B
▲ +16.7% YoY
Net Income (TTM)
$535M
▲ +422.3% YoY
Op. Margin
20.34%
▲ +9.7pp YoY
ROIC
10.87%
▲ +5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$756M
▲ +45.3% YoY
Op. Cash Flow (TTM)
$910M
▲ +44.7% YoY
Net Debt
-$483M
Net Cash Position
Cash & Equiv.
$595M
5Y CAGR: +30.1%
5Y CAGR: +34.2%
Continue Research
SourceComputed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Globus Medical (GMED) overvalued?
At a P/E of 19.7 and a price-to-free-cash-flow of 13.6, Globus Medical (GMED) trades below a two-stage DCF intrinsic value of about $281.14 per share, so at $76.71 the stock looks undervalued (266.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Globus Medical scores 72/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Globus Medical's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $281.14 per share for GMED, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $210.85. At today's $76.71, that puts the stock about 266.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Globus Medical a high-quality business?+
Globus Medical scores 72 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 20.3% operating margin and a 10.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Globus Medical a good stock to buy right now?+
That depends on valuation and quality together, not either alone. GMED currently trades below its estimated intrinsic value and scores 72/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.